0001734005 2026-07-20 2026-07-20 0001734005 dei:FormerAddressMember 2026-07-20 2026-07-20 true 0001734005 8-K/A 2026-07-20 Niki BioSolutions, Inc. DE 001-38764 42-3265309 116 Village Boulevard Suite 200 Princeton NJ 08540 609 951-2222 Aptorum Group Limited 17 Hanover Square London W1S 1BN GB false false false false Common stock, par value $0.0001 per share NIKI NASDAQ false As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 20, 2026 (the “Original Form 8-K”), on that same day (the “Closing Date”), after obtaining the requisite shareholder approval and satisfying the closing conditions, Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited) (the “Company”) consummated its previously announced merger (the “Closing”) pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”), between Aptorum and DiamiR Biosciences Corp., a Delaware corporation (“DiamiR”), pursuant to which, among other matters, Aptorum was to form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”).